Flutemetamol

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Flutemetamol
Accession Number
DB15058
Type
Small Molecule
Groups
Investigational
Description

Flutemetamol is under investigation in clinical trial NCT02353949 (Investigating the Clinical Consequences of Flutemetamol-PET-scanning).

Structure
Thumb
Synonyms
Not Available
Categories
UNII
0F3M7032P5
CAS number
637003-10-2
Weight
Average: 274.31
Monoisotopic: 274.057612319
Chemical Formula
C14H11FN2OS
InChI Key
VVECGOCJFKTUAX-UHFFFAOYSA-N
InChI
InChI=1S/C14H11FN2OS/c1-16-11-4-2-8(6-10(11)15)14-17-12-5-3-9(18)7-13(12)19-14/h2-7,16,18H,1H3
IUPAC Name
2-[3-fluoro-4-(methylamino)phenyl]-1,3-benzothiazol-6-ol
SMILES
CNC1=C(F)C=C(C=C1)C1=NC2=C(S1)C=C(O)C=C2

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
8282919
RxNav
1486026
ChEMBL
CHEMBL579205
ZINC
ZINC000034220093
Wikipedia
Flutemetamol_(18F)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingSupportive CareCardiac Amyloidosis1
2Active Not RecruitingScreeningAlzheimer's Disease (AD)1
2CompletedDiagnosticAlzheimer's Disease (AD) / Healthy Volunteers / Mild Cognitive Impairment (MCI)1
2, 3RecruitingDiagnosticAtherosclerosis1
3CompletedDiagnosticAlzheimer's Disease (AD) / Mild Cognitive Impairment (MCI)2
3CompletedDiagnosticBrain Fibrillarab Levels1
3CompletedDiagnosticHealthy Volunteers1
3CompletedDiagnosticHydrocephalus, Normal Pressure1
3TerminatedDiagnosticAlzheimer's Disease (AD) / Dementias / Mild Cognitive Impairment (MCI)1
3TerminatedDiagnosticHydrocephalus, Normal Pressure1
Not AvailableRecruitingNot AvailableAlzheimer's Disease (AD) / Dementias / Mild Cognitive Impairment (MCI)1
Not AvailableRecruitingDiagnosticBreast Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0135 mg/mLALOGPS
logP4.16ALOGPS
logP3.45ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)9.23ChemAxon
pKa (Strongest Basic)2.89ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area45.15 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity84.62 m3·mol-1ChemAxon
Polarizability28.21 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:45 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates